Stock DVAX DYNAVAX TECHNOLOGIES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
11.39 USD +2.52% Intraday chart for Dynavax Technologies Corporation +3.26% -18.53%
May. 14 Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data MT
May. 14 Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data
MT
Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA
DJ
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
RE
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
PR
Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S
CI
Transcript : Dynavax Technologies Corporation, Q1 2024 Earnings Call, May 08, 2024
Dynavax Technologies: Q1 Earnings Snapshot
AQ
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M
MT
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
PR
Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024
CI
Dynavax Technologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Dynavax Technologies : Additional proxy soliciting material – supplement
PU
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
PR
Dynavax Technologies Corporation Announces Chief Financial Officer Changes
CI
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
PR
Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue
MT
Transcript : Dynavax Technologies Corporation, Q4 2023 Earnings Call, Feb 22, 2024
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M
MT
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DVAX Stock
  4. News Dynavax Technologies Corporation
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW